Cinrebafusp alfa not checked

Pieris Pharmaceuticals, Inc. · PRS-343 · HER2/41BB Bispecific

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
HER2-positive Gastric Cancer
Main trialPhase 2
“A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.”In the company’s words, NCT05190445 on ClinicalTrials.gov
Other names
PRS-343 · HER2/41BB Bispecific

Other drugs for HER2-positive Gastric Cancer

All 208 drugs for HER2-positive Gastric Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 1 Feb 2023 Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Phase 1Completed 11 Aug 2022 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Phase 1Completed 1 Dec 2023 PRS-343 in HER2-Positive Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cinrebafusp alfa

Following is part of Solo: you see every change to Cinrebafusp alfa the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in